YARTEMLEA

narsoplimab · Omeros Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for YARTEMLEA, covering 2025-12-23 to 2026-07-15. Get the full timeline:

Most recent: EMA Opinion under re-examination: Yartemlea (narsoplimab) — Omeros Ireland Limited